Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
HER2 blockade
Description:
Therapeutic inhibition of HER2 receptor signaling, typically to suppress growth of HER2-dependent cancers.
Primary topic:
HER2/EGFR in Cancer Research (40%)
Related topics:
HER2/EGFR in Cancer Research (40%),
Cancer Immunotherapy and Biomarkers (18%),
Breast Cancer Treatment Studies (8%)
OpenAlex ID:
keywords/her2-blockade
Curcumin: the Indian Solid Gold
2007
·
Bharat B. Aggarwal
, Chitra Sundaram
, et al.
·
Springer eBooks
·
1,940
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
2021
·
Yelena Y. Janjigian
, Akihito Kawazoe
, et al.
·
Nature
·
778
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
2002
·
F Michael Yakes
, Wichai Chinratanalab
, et al.
·
PubMed
·
705
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2023
·
Yelena Y Janjigian
, Akihito Kawazoe
, et al.
·
The Lancet
·
630
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer
2015
·
Eunice L. Kwak
, Leanne G. Ahronian
, et al.
·
Cancer Discovery
·
188
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
2018
·
Kanika Bajaj Pahuja
, Thong T. Nguyen
, et al.
·
Cancer Cell
·
172
PDF
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
·
Celina García-García
, Yasir H. Ibrahim
, et al.
·
Clinical Cancer Research
·
168
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
2018
·
Giulia Siravegna
, Luca Lazzari
, et al.
·
Cancer Cell
·
165
PDF
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
2019
·
E. Krasniqi
, G. Barchiesi
, et al.
·
Journal of Hematology & Oncology
·
143
PDF
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
2014
·
Jihun Kim
, Cameron Fox
, et al.
·
Journal of Clinical Investigation
·
140
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
2024
·
José Manuel Pérez-García
, Javier Cortés
, et al.
·
The Lancet
·
133
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
2022
·
Akihiro Ohba
, Chigusa Morizane
, et al.
·
Journal of Clinical Oncology
·
107
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2 -Amplified Gastrointestinal Carcinomas
2015
·
Simonetta M. Leto
, Francesco Sassi
, et al.
·
Clinical Cancer Research
·
106
PDF
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
2014
·
Y-K Kang
, S Y Rha
, et al.
·
British Journal of Cancer
·
104
PDF
Cardiovascular Side-Effects of Modern Cancer Therapy
2010
·
Manabu Minami
, Shigemi Matsumoto
, et al.
·
Circulation Journal
·
93
PDF
Pertuzumab: Optimizing HER2 Blockade
2013
·
Otto Metzger-Filho
, Eric P. Winer
, et al.
·
Clinical Cancer Research
·
90
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
2019
·
Luca Lazzari
, Giorgio Corti
, et al.
·
Clinical Cancer Research
·
81
PDF
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
2019
·
Charlotte I. Stroes
, Sandor Schokker
, et al.
·
Journal of Clinical Oncology
·
77
PDF
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
2013
·
Zev A. Wainberg
, Adrian Anghel
, et al.
·
Molecular Cancer Therapeutics
·
70
Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade
2023
·
Meng He
, Zi-Fan Chen
, et al.
·
Journal for ImmunoTherapy of Cancer
·
69
PDF
Better Together: Targeted Combination Therapies in Breast Cancer
2015
·
Elisa Zanardi
, Giacomo Bregni
, et al.
·
Seminars in Oncology
·
61
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
2019
·
Aïda Sampera
, Francisco Javier Sánchez-Martín
, et al.
·
Molecular Cancer Therapeutics
·
58
Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
2015
·
M. Mates
, G.G. Fletcher
, et al.
·
Current Oncology
·
48
PDF
HER2 targeted therapy in colorectal cancer: New horizons
2022
·
Ali Abdulnabi Suwaidan
, David K. Lau
, et al.
·
Cancer Treatment Reviews
·
47
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials
2024
·
Aranzazu Fernandez-Martinez
, Mattia Rediti
, et al.
·
JAMA Oncology
·
45
PDF
Show more works
View as search
Works count:
301
Citation count:
7,109
Year
Topic
Type